Karl Landert Chief Executive Officer of eClinicalHealth, said:
“We are very happy about this development which will strengthen eClinicalHealth’s scalability and capabilities. As a wholly owned subsidiary of Cambridge Cognition we can deliver Decentralised Clinical Trials (DCT) on a global scale and become a world-leading DCT platform. We will jointly develop offerings for the Central Nervous systems therapeutic area where DCT elements show the highest growth rate.”
eClinicalHealth (operating as Clinpal™) is a digital technology provider of innovative decentralized approaches for the delivery of clinical trials that is working on trials for three of the top ten largest global pharmaceutical companies. With a patient-centric platform that connects patients, sites and pharmaceutical companies, the technology enables all the essential steps in a clinical trial. eClinicalHealth has been selected to provide the core platform for the Trials@Home proof-of-concept RADIAL study, having been a valued consortium member working alongside 30 EFPIA and Academic and SME partners since 2019.
About Cambridge Cognition
Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company’s software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
For further information visit https://www.cambridgecognition.com/news/entry/cambridge-cognition-acquires-eclinicalhealth